Crolibulin

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameCrolibulin
Drug Alias NameCrolibulinum克洛布林克罗布林CrolibulinaCrinobulin +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTubulin inhibitorsVascular disrupting agents (VDA)Apoptosis inducers
TargetsTubulin
Therapy Area/IndicationsSolid tumoursThyroid Carcinoma, AnaplasticLymphoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesImmune Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesImmune Pharmaceuticals IncNational Cancer Institute
Inactive CompaniesEpicept Co
Active IndicationsLymphoma
Inactive IndicationsSolid tumoursThyroid Carcinoma, AnaplasticNeoplasms

Other Information

ATC CodeN/A
Related LinksKEGG